atai Life Sciences announces positive topline data from Phase 2a treatment-resistant depression study
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced positive topline data from Part 2 of Beckley Psytech's Phase 2a study of BPL-003, an intranasal formulation of mebufotenin benzoate, in combination with selective serotonin reuptake inhibitors (SSRIs) for treatment-resistant depression (TRD). The open-label Phase 2a study evaluated the safety, efficacy, and pharmacokinetics of a single dose of BPL-003 in 12 patients with moderate-to-severe depression who had not responded to at least two prior treatments and were taking SSRIs.
atai Life Sciences shares gain momentum ahead of pivotal trial readouts
atai Life Sciences (NASDAQ:ATAI, ETR:9VC)' stock is poised to climb significantly, driven by a series of clinical catalysts this year and next, analysts at Jefferies wrote following the release of the company's first quarter results. The analysts repeated their ‘Buy' rating and $5 price target on atai, which traded up 11.8% at $1.60 on Thursday afternoon.
atai Life Sciences builds clinical momentum in first quarter of 2025
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has kicked off 2025 with strong momentum across its clinical pipeline ahead of expected key data readouts later this year and into 2026. Recent operational highlights include dosing the first patient in a Phase 2 trial of EMP-01 (oral R-MDMA) for social anxiety disorder and continued enrollment in the Elumina study evaluating VLS-01, a buccal film formulation of DMT, in treatment resistant depression.
atai Life Sciences CEO discusses major data readouts expected through 2025 - ICYMI
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO Dr Srinivas Rao talked with Proactive about the company's upcoming clinical milestones and strategic focus in 2025. Rao outlined four major clinical readouts across atai's pipeline of short-duration psychedelics, including updates on VLS-01, BPL-003, RL-007 and EMP-01.
Insiders Make Huge Purchases of These 4 Biotech Stocks
After a rough patch, it seems the biotech industry may be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more have high expectations.
atai Life Sciences entering catalyst-rich period with high-potential data readouts in 2025 and 2026
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is entering a pivotal period with data from several key trials expected in 2025 and 2026, analysts at Jefferies have highlighted following the company's fourth quarter update. “We see a catalyst-rich period with five-plus Phase 2/3 central nervous systems/neuro readouts in 2025 to 2026,” the analysts wrote in a note to clients.
atai Life Sciences prepares for data readouts from key clinical trials, extends operational runway
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said it saw significant progress in 2024 with key advancements in its clinical trials as it strengthened its financial position. The company successfully dosed its first patient in the Phase 2 Elumina trial for VLS-01, a buccal film formulation of DMT designed to treat treatment-resistant depression.
atai Life Sciences doses first patient in Phase 2 treatment-resistant depression trial
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that the first patient has been dosed in its Phase 2 Elumina trial of VLS-01, the company's oral transmucosal film formulation of DMT applied to the buccal surface, in participants with treatment-resistant depression. Topline results are expected from the first treatment phase of the trial in the first quarter of 2026.
atai Life Sciences-backed trial in treatment-resistant depression completes patient enrollment
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that patient enrollment has been completed in Beckley Psytech's Phase 2b trial evaluating BPL-003 in treatment-resistant depression (TRD), with topline results expected by mid-2025. The trial is assessing the efficacy and safety of a single dose of BPL-003, an intranasal formulation of mebufotenin benzoate developed by Beckley Psytech, in which atai is invested, designed for rapid and lasting antidepressant effects with minimal clinic time.
Atai: Following The Path That Spravato Laid And Moving Beyond It
Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds. Standing on the shoulders of Johnson & Johnson's Spravato.
atai Life Sciences completes public offering, raising $63.25M
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has closed is public offering of shares and the underwriter's option to purchase additional shares for gross proceeds of approximately $63.25 million before deductions. The company, a clinical-stage biopharmaceutical company focused on mental health treatments, offered about 26.2 million common shares for $2.10 per share, with the underwriter's purchasing an additional 3.9 million shares.
atai Life Sciences announces pricing of $55M public offering of shares
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said its registered underwritten offering of approximately 26.2 million shares will be priced at $2.10 per share to raise proceeds of $55 million. The underwriter has a 30-day option to purchase up to an additional approximately 3.9 million shares.
